Orion Oyj operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Orion Oyj with three other
pharmaceutical manufacturers in Europe:
of the United Kingdom
sales of £786.93 million [US$997.38 million]
of which 100%
was Buprenorphine Based Drugs),
(1.15 billion Euro [US$1.29 billion]
of which 84%
was Pharmaceuticals), and
Krka DD Novo Mesto
based in Slovenia
(1.17 billion Euro [US$1.31 billion]
of which 63%
was European Union).
During the year ended December of 2016, sales at
Orion Oyj were 1.07 billion Euro (US$1.20 billion).
increase of 5.7%
versus 2015, when the company's sales were 1.02 billion Euro.
This was the fifth consecutive year of sales increases at Orion Oyj
(and since 2011, sales have increased a total of 17%).
Sales of Pharmaceuticals Business saw an increase
6.4% in 2016, from
957.80 million Euro to 1.02 billion Euro.
Not all segments of Orion Oyj experienced an increase in sales in 2016:
sales of Diagnostica fell 5.2% to 54.80 million Euro.